Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12 502 M
EBIT 2017 3 725 M
Net income 2017 2 086 M
Debt 2017 12 843 M
Yield 2017 -
Sales 2018 13 080 M
EBIT 2018 4 021 M
Net income 2018 2 303 M
Debt 2018 10 923 M
Yield 2018 -
P/E ratio 2017 13,75
P/E ratio 2018 12,53
EV / Sales2017 2,65x
EV / Sales2018 2,39x
Capitalization 20 334 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
06/22Shareholder meeting
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/17 MYLAN : Theravance Biopharma and Mylan to Present Additional Data for Revefenaci..
05/16 MYLAN : to Present at UBS Global Healthcare Conference
05/16 MYLAN : Honors National Women's Health Week to Empower Women to Take Control of ..
05/11 GSK escapes Advair hit for now as second generic bid fails
05/10DJMARKET SNAPSHOT : Nasdaq Closes At Record For 4th Straight Day As Dow Slips In F..
05/10DJMARKET SNAPSHOT : Stock Market Flat As Investors Digest Trump's Firing Of FBI's ..
05/10 Mylan says disagrees with FDA over generic Advair delay
05/10DJMARKET SNAPSHOT : Stock Market Falls After Trump's Firing Of FBI's Comey Raises ..
05/10 MYLAN NV : Investor Network: Mylan N.V. to Host Earnings Call
More news
Sector news : Pharmaceuticals - NEC
03:18p Cross-border M&A between U.S. and European firms at 10 year high
08:32aDJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 49,0 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%20 334
JOHNSON & JOHNSON10.23%342 117
ROCHE HOLDING LTD.14.79%235 098
NOVARTIS AG6.28%210 347
PFIZER INC.-0.06%193 303
MERCK & CO., INC.8.34%174 449
More Results